Condition: Fever · Adverse Event Following Immunisation · Sponsor: Duke University
This is a prospective, randomized, open-label clinical trial to evaluate the safety of administration of respiratory syncytial virus (RSV) preventive monoclonal antibody and other routine childhood vaccines given simultaneously at Visit 1, as compared to sequential administration of respiratory syncytial virus (RSV) preventive monoclonal antibody and other vaccines at separate visits (Visits 1 and 2).
This description comes directly from the study's public registry record.
Michael J Smith, MD · 919 684 6335 · michael.j.smith@duke.edu
Emily A Randolph, MBA · 919 385 5785 · emily.randolph@duke.edu
Always discuss trial participation with your own doctor first.
| Kaiser Permanente Northern California | Oakland, California, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Recruiting |
| Centers for Disease Control and Prevention | Atlanta, Georgia, United States | Active Not Recruiting |
| Columbia University | New York, New York, United States | Recruiting |
| Duke University | Durham, North Carolina, United States | Recruiting |
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07158814